Closed

NHS Framework for the North of England, Branded Medicines - Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®)

NHS England · £431,955,441 · closes 20 Oct 2021

£431,955,441

Estimated value

Closed

Deadline

20 Dec 2023

Published

This tender has closed.

See what's open in medical equipment and pharmaceuticals, or get contracts like this in your inbox each morning — free.

Set up free alerts Open medical equipment and pharmaceuticals tenders

About this contract

Offer reference number: CM/PHR/20/5600 CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.